Response to cardiac resynchronization therapy: is it time to expand the criteria?

Henneke Versteeg1, Angélique A Schiffer, Jos W Widdershoven

  • 1CoRPS-Center of Research on Psychology in Somatic diseases, Department of Medical Psychology, Tilburg University, The Netherlands.

Insights

Cardiac resynchronization therapy (CRT) improves heart failure but many patients do not respond. Current measures of CRT response neglect patient-reported outcomes and psychological factors, necessitating broader assessment criteria.

Area of Science:

  • Cardiology
  • Heart Failure Management
  • Medical Device Therapy

Background:

  • Cardiac resynchronization therapy (CRT) is a treatment for advanced congestive heart failure (CHF) patients with prolonged QRS intervals.
  • While many patients benefit, 10-40% are non-responders, highlighting a gap in treatment efficacy.
  • Current definitions of CRT response lack consensus and may not fully capture patient outcomes.

Purpose of the Study:

  • To discuss existing definitions of CRT response and their limitations.
  • To recommend expanding response criteria for better clinical utility.
  • To explore the role of patient-reported outcomes and psychological factors.

Main Methods:

  • Literature analysis of established CRT response measures.
  • Review of case reports.
  • Examination of patient-reported symptoms and quality of life.

Main Results:

  • Established measures (NYHA class, echocardiographic, hemodynamic, neurohormonal) poorly correlate with patient-reported symptoms and quality of life.
  • Psychological factors' impact on CRT outcomes is largely overlooked.
  • Existing metrics fail to adequately represent the patient experience post-CRT.

Conclusions:

  • Routinely assess patient health status post-CRT using disease-specific questionnaires.
  • Investigate determinants of CRT response, including psychological factors like personality and depression.
  • Improved assessment can lead to better secondary treatment and prognosis for CHF patients undergoing CRT.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...